MedRhythms Announces Availability of Movive™ for Parkinson's Disease (PD) for Veterans

PORTLAND, Maine, April 2, 2025 /PRNewswire/ -- MedRhythms today announced that Movive^™, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS).

"A growing number of Veterans face barriers to consistent, effective neurorehabilitation, particularly for gait and motor function," said Joel Behnke, Chief Commercial Officer at MedRhythms. "With Movive, MedRhythms is not only supporting the VA's focus on home-based, Veteran-centered care—we're also expanding access to RAS therapy to help close key gaps in Parkinson's treatment."

Movive is designed to expand access to individualized, progressive, and engaging rhythmic auditory stimulation (RAS) that is autonomously delivered for use in home and community settings. RAS has been studied extensively in PD and is included in many clinical pathways, including the American Physical Therapy Association's (APTA) Clinical Practice Guidelines for Parkinson's Disease (Osborne et al., 2022).

Dr. Alexander Pantelyat, the Co-Founder and Director of the Johns Hopkins Center for Music and Medicine, and Co-Principal Investigator of a recent feasibility study (Zajac et al., 2023) evaluating Movive, highlighted the strong engagement with the therapy: "Movive delivers Rhythmic Auditory Stimulation (RAS) to individuals with Parkinson's disease in the home using both familiar and newly discovered music across a variety of genres. Impressively, PD participants increased, on average, their daily step count by 28% and their moderate intensity activity by 56% from baseline. A typical PD patient decreases significantly on both of these measures over the course of their disease."

Dr. Terry Ellis, Professor and Chair of the Department of Physical Therapy at Boston University, and Principal Investigator on an additional study evaluating Movive (unpublished data on file) continued: "Movive was also found to improve stride time variability compared to an active control group, exceeding a minimum clinically important difference, and suggesting improvement in automaticity of walking."

MedRhythms and Lovell Government Services build on their previously announced partnership with the launch of Movive. Lovell will serve as Movive's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, providing access to all government organizations and Federal healthcare systems, including the Veterans Health Administration (VHA), the Military Health System (MHS), and Indian Health Services (IHS). Movive is listed on the Federal Supply Schedule (FSS) and GSA Advantage federal contracts. Listing products with Lovell streamlines the acquisition process and assists government agencies in meeting their SDVOSB procurement goals.

To learn more about Movive, visit: https://movive.com
For technical specifications or clinical onboarding support, contact: [email protected]

April is Parkinson's Disease Awareness Month
PD is the fastest growing neurodegenerative disease in the world. According to the Parkinson's Foundation, nearly one million Americans have PD, including 110,000 Veterans, making it the second most common neurodegenerative disease. Gait impairment and loss of motor function are defining symptoms of PD, with walking and mobility as the number one patient-reported challenge.

About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.

Learn more at www.lovellgov.com

About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music (via a partnership with Universal Music Group) with advanced neuroscience to target neural circuitry. The company is developing a pipeline of digital therapeutics across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. The company's product for chronic stroke walking deficits received Breakthrough Device Designation in 2020, and the company raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine. For more information, visit www.medrhythms.com.

Forward-Looking Statements
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.

Contact
[email protected]

SOURCE MedRhythms